[6] |
Edelmann F,Knosalla C,M■rike K,et al.Chronic Heart Failure[J].Dtsch Arztebl Int,2018,115(8):124-130.
|
[11] |
赖凌燕,蒋辉.尼可地尔治疗稳定型心绞痛患者的疗效及药学分析[J].中国医药科学,2021,11(22):69-72.
|
[12] |
张远恒,陈绪江.尼可地尔治疗冠状动脉慢血流的临床效果[J].中国当代医药,2020,27(16):47-50.
|
[1] |
Muneer K,Nair A.Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease-Demystifying controversies[J].Indian Heart J,2017, 69(3):371-374.
|
[3] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
|
[4] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
|
[2] |
Mortensen AL,Rosenfeldt F,Filipiak KJ.Effect of coenzyme Q10 in Europeans with chronic heart failure:A sub-group analysis of the Q-SYMBIO randomized double-blind trial[J].Cardiol J,2019,26(2):147-156.
|
[5] |
Okazaki H,Shirakabe A,Hata N,et al.Prognostic benefit of acute heart failure associated with atherosclerosis:the importance of prehospital medication in patients with severely decompensated acute heart failure[J].Heart Vessels,2018,33(12):1496-1504.
|
[7] |
Singhania G,Ejaz AA,McCullough PA,et al.Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization-a Review[J].Rev Cardiovasc Med,2019,20(3):111-120.
|
[8] |
Zozina VI,Covantev S,Goroshko OA,et al.Coenzyme Q10 in Cardiovascular and Metabolic Diseases:Current State of the Problem[J].Curr Cardiol Rev,2018,14(3):164-174.
|
[9] |
Xing Y,Liu C,Wang H,et al.Protective Effects of Nicorandil on Cardiac Function and Left Ventricular Remodeling in a Rat Model of Ischemic Heart Failure[J].Arch Med Res,2018,49(8):583-587.
|
[10] |
Harada K,Yamamoto T,Okumura T,et al.Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes:A randomized,controlled trial[J].Eur Heart J Acute Cardiovasc Care,2017,6(4):329-338.
|
[13] |
赵静,葛晓丽,靳丽君,等.尼可地尔联合辅酶Q10治疗慢性心力衰竭的疗效及对血清炎性因子及氧化应激水平的影响[J].中西医结合心脑血管病杂志,2019,17(6):892-895.
|
[14] |
Kiyuna LA,Albuquerque RPE,Chen CH,et al.Targeting mitochondrial dysfunction and oxidative stress in heart failure:Challenges and opportunities[J].Free Radic Biol Med,2018,129:155-168.
|
[15] |
Kalter-Leibovici O,Freimark D,Freedman LS,et al.Disease management in the treatment of patients with chronic heart failure who have universal access to health care:a randomized controlled trial[J].BMC Med,2017,15(1):90.
|
[16] |
Prabhu SD,Frangogiannis NG.The Biological Basis for Cardiac Repair After Myocardial Infarction:From Inflammation to Fibrosis[J].Circ Res,2016,119(1):91-112.
|
[17] |
Waldman M,Cohen K,Yadin D,et al.Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ′SIRT1 and PGC-1α′[J].Cardiovasc Diabetol,2018,17(1):111.
|
[18] |
Alawieh H,Chemaly TE,Alam S,et al.Towards Point-of-Care Heart Failure Diagnostic Platforms:BNP and NT-proBNP Biosensors[J].Sensors (Basel),2019,19(22):5003.
|
[19] |
黄冬梅,黄刚,余冬梅,等.血清指标联合超声检查指标对慢性心力衰竭的诊断价值分析[J].实用心脑肺血管病杂志,2021,29(11):16-20.
|
[20] |
陈蓉,郭俊芳,尹春阳,等.血浆 B 型钠尿肽水平对慢性心力衰竭的早期诊断价值研究[J].中国全科医学,2019, 22(S2):50-52.
|
[21] |
Kuster N ,Huet F,Dupuy AM,et al.Multimarker approach including CRP,sST2 and GDF-15 for prognostic stratification in stable heart failure[J].ESC Heart Fail,2020,7(5):2230-2239.
|